Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN (ZYPITAMAG) TO PEOPLE LIVING WITH HIV WINNIPEG, CANADA –...
VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage...
LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas, April 30, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical...
LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta Further Strengthened Management Team OncXerna Global Licensing Agreement for Navicixizumab...
LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -11.1111111111 | 0.99 | 0.99 | 0.87 | 800 | 0.88 | CS |
| 4 | 0 | 0 | 0.88 | 1.09 | 0.84 | 1965 | 0.92765303 | CS |
| 12 | -0.13 | -12.8712871287 | 1.01 | 1.15 | 0.84 | 1610 | 0.96313045 | CS |
| 26 | -0.18 | -16.9811320755 | 1.06 | 1.26 | 0.84 | 2437 | 1.02933349 | CS |
| 52 | -0.62 | -41.3333333333 | 1.5 | 1.62 | 0.84 | 2540 | 1.18586466 | CS |
| 156 | -0.11 | -11.1111111111 | 0.99 | 1.8 | 0.8 | 3430 | 1.21762254 | CS |
| 260 | -4.27 | -82.9126213592 | 5.15 | 5.17 | 0.7 | 5630 | 1.35857333 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
